Myriad Genetics, Inc. is a molecular diagnostic company that develops and markets tests that assess a person's risk of developing certain cancers, the presence of certain inherited genetic conditions, and the likelihood of responding to certain drugs. The company was founded in 1991 and is headquartered in Salt Lake City, Utah. Myriad Genetics operates through two segments: Diagnostics and Other. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment. The Other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients.